William K. McVicar insider trades: Salarius Pharmaceuticals (SLRX) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where William reports to the SEC
Open-market buys and sales
2 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jun 6, 2022 | SLRX | ↑ Buy | 26,553 | $0.19 | $5K | McVicar Family Trust | Jun 7, 2022 (1d) |
| Feb 11, 2020 | SLRX | ↑ Buy | 8,700 | $1.15 | $10K | Direct | Feb 12, 2020 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other SLRX insiders
Open-market trades in the last 12 months
About William K. McVicar's insider trades
William K. McVicar is a director at Salarius Pharmaceuticals (SLRX). Since Feb 11, 2020, William has reported 2 open-market purchases worth $15K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (13 filings), other transactions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every SLRX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.